These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 30199249)
1. Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N Woodward HL; Innocenti P; Cheung KJ; Hayes A; Roberts J; Henley AT; Faisal A; Mak GW; Box G; Westwood IM; Cronin N; Carter M; Valenti M; De Haven Brandon A; O'Fee L; Saville H; Schmitt J; Burke R; Broccatelli F; van Montfort RLM; Raynaud FI; Eccles SA; Linardopoulos S; Blagg J; Hoelder S J Med Chem; 2018 Sep; 61(18):8226-8240. PubMed ID: 30199249 [TBL] [Abstract][Full Text] [Related]
2. Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach. Innocenti P; Woodward HL; Solanki S; Naud S; Westwood IM; Cronin N; Hayes A; Roberts J; Henley AT; Baker R; Faisal A; Mak GW; Box G; Valenti M; De Haven Brandon A; O'Fee L; Saville H; Schmitt J; Matijssen B; Burke R; van Montfort RL; Raynaud FI; Eccles SA; Linardopoulos S; Blagg J; Hoelder S J Med Chem; 2016 Apr; 59(8):3671-88. PubMed ID: 27055065 [TBL] [Abstract][Full Text] [Related]
3. High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Anderhub SJ; Mak GW; Gurden MD; Faisal A; Drosopoulos K; Walsh K; Woodward HL; Innocenti P; Westwood IM; Naud S; Hayes A; Theofani E; Filosto S; Saville H; Burke R; van Montfort RLM; Raynaud FI; Blagg J; Hoelder S; Eccles SA; Linardopoulos S Mol Cancer Ther; 2019 Oct; 18(10):1696-1707. PubMed ID: 31575759 [TBL] [Abstract][Full Text] [Related]
4. Studies of Interaction Mechanism between Pyrido [3,4- Xing C; Zhou X; Chen C; Sun W; Zheng Q; Liang D Molecules; 2021 Aug; 26(16):. PubMed ID: 34443663 [TBL] [Abstract][Full Text] [Related]
5. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152 [TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK. Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255 [TBL] [Abstract][Full Text] [Related]
7. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606 [TBL] [Abstract][Full Text] [Related]
8. Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase. Schulze VK; Klar U; Kosemund D; Wengner AM; Siemeister G; Stöckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Holton SJ; Briem H; Marquardt T; Schirok H; Jautelat R; Bohlmann R; Nguyen D; Fernández-Montalván AE; Bömer U; Eberspaecher U; Brüning M; Döhr O; Raschke M; Kreft B; Mumberg D; Ziegelbauer K; Brands M; von Nussbaum F; Koppitz M J Med Chem; 2020 Aug; 63(15):8025-8042. PubMed ID: 32338514 [TBL] [Abstract][Full Text] [Related]
9. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188 [TBL] [Abstract][Full Text] [Related]
10. Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1). Naud S; Westwood IM; Faisal A; Sheldrake P; Bavetsias V; Atrash B; Cheung KM; Liu M; Hayes A; Schmitt J; Wood A; Choi V; Boxall K; Mak G; Gurden M; Valenti M; de Haven Brandon A; Henley A; Baker R; McAndrew C; Matijssen B; Burke R; Hoelder S; Eccles SA; Raynaud FI; Linardopoulos S; van Montfort RL; Blagg J J Med Chem; 2013 Dec; 56(24):10045-65. PubMed ID: 24256217 [TBL] [Abstract][Full Text] [Related]
11. X-ray Crystal Structure-Guided Design and Optimization of 7 Lee Y; Kim H; Kim H; Cho HY; Jee JG; Seo KA; Son JB; Ko E; Choi HG; Kim ND; Kim I J Med Chem; 2021 May; 64(10):6985-6995. PubMed ID: 33942608 [TBL] [Abstract][Full Text] [Related]
12. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads. Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538 [TBL] [Abstract][Full Text] [Related]
13. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity. Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791 [TBL] [Abstract][Full Text] [Related]
14. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. Wang S; Zhang M; Liang D; Sun W; Zhang C; Jiang M; Liu J; Li J; Li C; Yang X; Zhou X Eur J Med Chem; 2019 Aug; 175():247-268. PubMed ID: 31121430 [TBL] [Abstract][Full Text] [Related]
15. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of a new class of 7H-pyrrolo[2,3-d]pyrimidine derivatives as Mps1 inhibitors for the treatment of breast cancer. Li X; Wei W; Tao L; Zeng J; Zhu Y; Yang T; Wang Q; Tang M; Liu Z; Yu L Eur J Med Chem; 2023 Jan; 245(Pt 1):114887. PubMed ID: 36370549 [TBL] [Abstract][Full Text] [Related]
17. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817 [TBL] [Abstract][Full Text] [Related]
18. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability. Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790 [TBL] [Abstract][Full Text] [Related]
19. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides. Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312 [TBL] [Abstract][Full Text] [Related]
20. Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents. Liang C; Zhou Y; Xin L; Kang K; Tian L; Zhang D; Li H; Zhao Q; Gao H; Shi Z Eur J Med Chem; 2024 Jul; 273():116504. PubMed ID: 38795520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]